New Option Soon for Some European Patients With Leukemia
Gilteritinib has been recommended for approval for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.
Related Articles
29th Annual Acute Leukemia Forum 2025 | La Jolla, California
Register now and explore groundbreaking advancements in acute leukemia and myelodysplasia treatment at ALF 2025. Stay informed with the latest innovations shaping the future of…
Key Lymphoma Abstracts from ASH 2024
Join us live as Dr Alex Herrera and Dr Matthew Lunning discuss key lymphoma data presented at the annual hematology meeting in San Diego! Drs…
29th Annual Acute Leukemia Forum 2025 | La Jolla, California
Register now and explore groundbreaking advancements in acute leukemia and myelodysplasia treatment at ALF 2025. Stay informed with the latest innovations shaping the future of…
Key Lymphoma Abstracts from ASH 2024
Join us live as Dr Alex Herrera and Dr Matthew Lunning discuss key lymphoma data presented at the annual hematology meeting in San Diego! Drs…